The introduction of biosimilars in the treatment of age-related macular degeneration (AMD) is raising concerns among physicians about cost-driven mandates and the autonomy to choose the best therapies ...

D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

Obstructive sleep apnea is associated with higher rates of age-related macular degeneration development and progression.

Types of wet AMD treatments. The main treatment involves eye injections of anti-VEGF drugs to stop problematic blood vessel growth. Options include aflibercept, bevacizumab, brolucizumab ...

Anti-VEGF therapy improves outcomes in retinal diseases by targeting neovascularization and macular edema, crucial in conditions like AMD and diabetic retinopathy. Optical coherence tomography is ...

The study included 29 eyes of 28 patients receiving intravitreal 2 mg/0.05 ml aflibercept injection for the treatment of wet AMD resistant to intravitreal ranibizumab injections. There were 11 ...

Ixo-vec is a potential best-in-class one-time gene therapy designed to deliver long-term efficacy, reduce the burden of frequent anti-VEGF and ...

"This is a historic moment for 4DMT as we become a Phase 3 company following our initiation of the 4FRONT-1 clinical trial,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.

For wet AMD, you can slow or stop symptoms and possibly reverse vision changes with anti-VEGF injections. Find out how wet AMD can affect vision loss and your eye health. AMD is a common age ...

Novel drug that inhibits both VEGF-A and Angiopoietin -2 have a promising role in management of wet AMD. Can we lower the risk of getting AMD? Embrace a healthier lifestyle to reduce the risk of ...

In the randomized, sham-controlled ARTEMIS study, patients will receive either a dose of ixo-vec or a standard care regimen of anti-VEGF Eylea.

Aflibercept for exudative AMD with persistent fluid on ranibizumab ... in eyes previously treated with other vascular endothelial growth factor ınhibitors. Am J Ophthalmol. 2013;156(1):23 ...